Life sciences news roundup: $175M for cell therapy; vaccine data; and more

HDT Bio’s first Brazilian affected person prepares to obtain a shot in its COVID-19 vaccine trial in that nation. (HDT Bio Photo)

It was once any other busy week in Seattle-area biotech.

Affini-T Therapeutics on Monday introduced $175 million in preliminary financing. The corporate targets to transport mobile treatments evolved at Fred Hutchinson Cancer Research Center into the health facility to regard forged tumors.

The week ended with Icosavax posting knowledge “below our expectations” on its COVID-19 vaccine, sending stocks sinking.

Meanwhile, HDT Bio’s COVID-19 vaccine is also slowed for a unique explanation why. The Seattle startup filed a lawsuit towards its India-based vaccine spouse, claiming that it stole its tech and refused to percentage medical trial knowledge. HDT Bio’s early trials in different international locations proceed.

Finally, the University of Washington’s Institute for Protein Design continues to invent new tactics to make medicine. Read on for his or her newest learn about, and different information from the Pacific Northwest — together with an inventory of virtual startups within the psychological well being box.  

Fred Hutch spinout Affini-T Therapeutics lands $175M for mobile treatments to regard forged tumors

Icosavax posts COVID-19 vaccine knowledge ‘below our expectations’ as stocks plummet greater than 60%

Seattle startup claims India-based drugmaker stole COVID-19 vaccine tech, seeks $950M

Univ. of Washington researchers to find new approach to design attainable therapeutics

An inventory of psychological well being startups within the Pacific Northwest, as pandemic fuels expansion for sector

Startup that targets to forestall tissue adhesions after surgical operation wins inaugural Apis well being pageant

Spirulina rising at Lumen Bioscience. (Lumen Photo)

And right here’s different lifestyles sciences information from around the Pacific Northwest and past:

  • Researchers from Lumen Bioscience exhibit their platform for making biologic medicine within the inexperienced algae Spirulina in a new learn about in Nature Biotechnology.
  • UW immunologist Marion Pepper and her colleagues checked out responses to COVID-19 vaccination in individuals who had prior to now been inflamed with the virus, appearing that they produce extra tough immunity than other people secure most effective by way of the pictures.
  • UW geneticist Evan Eichler and his colleagues launched a learn about taking a look at “de novo” mutations that stand up spontaneously within the genome. The researchers may just fortify detection by way of about 25% with their manner.
  • A characteristic tale in Nature by way of science journalist Roxanne Khamsi explores how Eichler and his colleagues are making a reference human genome that accounts for human range. The mission is dubbed the “Human Pangenome Project.”
  • In a separate mission, the “All of Us” analysis program launched just about 100,000 entire genome sequences from numerous members. The UW’s Northwest Genomics Center is one in all 3 facilities concerned within the mission. UW participants come with Eichler, geneticist Gail Jarvik and the overdue Deborah Nickerson.


  • A podcast known as Big Brains options UW professor Marco Pravetoni, who talks about his vaccine designed to counteract opioid dependancy. Praventoni leads the brand new UW Center for Medication Development for Substance Use Disorders.
  • Another podcast options Institute for Protein Design director David Baker. The name of the display is “The communal brain.”
  • While at the mind theme, take a look at how the Allen Institute processes its samples of that organ, in this tale from the group.  


  • Microsoft CEO Satya Nadella lately invested in Silicon Valley virtual well being corporate Notable, which makes affected person scheduling gear and different tool to simplify administrative healthcare duties.

Vaccines and medication:

  • As the Icosavax COVID-19 vaccine hits tough waters, any other vaccine in accordance with the similar design has complicated thru later-stage trials. The govt of South Korea ordered 10 million doses in anticipation of its approval.
  • A brand new immune “checkpoint” drug were given the nod from the U.S. Food and Drug Administration. The company authorized relatlimab (a LAG-3 inhibitor) together with Opdivo for sufferers with metastatic melanoma or melanoma that may’t be handled with surgical operation. Both medicine are made by way of Bristol Myers Squibb, which does immuno-oncology R&D within the Seattle field. This tale has some nice background at the new drug.

Seattle-area reaction to Ukraine:

  • Some Washington biotech firms like Seagen and Absci are matching worker donations to Ukrainian humanitarian efforts. So is Seattle-based Phase Genomics, led by way of Ivan Liachko, who grew up in Kyiv. Bioprocess Online talks to Liachko about his efforts to mobilize the biotech group.

Source hyperlink

Leave a Reply

Your email address will not be published.